Impact of Magnetic Resonance and Biomarkers for Screening for Prostate Cancer. Cost-effectiveness Analysis

Establish if There Are Differences Between Transrectal and Transperineal Prostatic Biopsy Schemes in Both Cases With and Without MRI Clinical Trial

— RMPBX201801  

Official title:

Impact of Magnetic Resonance and Biomarkers for Screening for Prostate Cancer With Different Approaches. Cost-effectiveness Analysis (RMP-BX 2018-01)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04283032
• Other study ID #: PI18/01560
• Status: Not yet recruiting
• Start date: March 1, 2020
• Est. completion date: December 31, 2021

Study information

• Verified date: February 2020
• Source: Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
• Contact: Francisco Gomez Veiga
• Phone: 923291100
• Email: fgveiga[@]telefonica.net
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Objectives: To establish if there are differences between an ultrasound-guided transrectal prostate biopsy (BPTE) and a transperineal prostatic biopsy (BPTP) with and without a multiparametric Magnetic Resonance (RMmp) in patients with clinical suspicion of prostate cancer (PC) to first prostatic biopsy in terms of:

1. Rate of detection and diagnosis of prostate cancer.

2. Aggressiveness of the detected tumors.

3. Association of the marker [-2] proPSA and the prostate cancer health index (PHI) and microRNAs for the diagnosis of tumors.

4. Adverse effects of the intervention and subjective perception of the patient: pain and degree of satisfaction, and impairment of quality of life.

5. Cost-effectiveness analysis of the different intervention options.

Study Design: Randomized, single-blind prospective clinical study to compare four schemes:

RMmp + BPTE vs. BPTE 12 cylinders vs RMmp + BPTP vs BPTP 12 cylinders.

Study population: Patients with clinical suspicion of prostate cancer with PSA between 3-20 ng / mL and normal or abnormal rectal examination, candidates for a first prostate biopsy.

Research techniques: BPTE standard of 12 cylinders compared to RMmp previous to BPTE vs BPTP of 12 cylinders compared to BPTP with previous RMmp.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 628
• Est. completion date: December 31, 2021
• Est. primary completion date: June 30, 2020
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 45 Years to 75 Years

Eligibility

Inclusion Criteria:

• Signature of informed consent prior to performing any of the specific procedures of the study

• Age between 50 * - 75 years (* 45 years, if family history)

• Patients with clinical suspicion of prostate cancer

• Indication of a first biopsy during the study period.

• Life expectancy greater than 10 years.

Exclusion Criteria:

• Patients previously randomized in the present study.

• Patients submitted prior to a prostate biopsy.

• Patients with a previous diagnosis of prostate cancer and / or previous prostate surgery.

• Patients with a previous episode of acute prostatitis of infectious origin in the 3 months prior to inclusion in the study.

• Patients with an active urinary tract infection and / or any previous pathology of severity in the 3 months prior to inclusion.

• Impossibility of performing transrectal or transperineal biopsy and / or magnetic resonance.

• Patients who have received hormonal treatment prior to androgen blockade in the 6 months prior to inclusion in the study.

• History of other tumors.

Related Conditions & MeSH terms

• Aggression
• Establish if There Are Differences Between Transrectal and Transperineal Prostatic Biopsy Schemes in Both Cases With and Without MRI
• Establish the Association of the Tumor Biomarker in the Early Detection and Aggressiveness of Tumors
• Establish the Efficacy Between the Four Schemes in Terms of Morbidity Associated With the Technique
• Establish the Efficacy Between the Four Schemes in Terms of the Aggressiveness of the Tumors According to the Gleason Classification
• Establish the Efficacy Between the Four Schemes in Terms of the Patient's Subjective Perception Regarding Pain and Quality of Life
• Establish the Possible Interaction Between Biomarkers and Resonance in Different Prostate Biopsy Models to Define Tumor Presence and / or Tumor Aggressiveness
• Establish the Possible Relationship Between the Expression Profiles of the microRNAs
• Neoplasms
• Prostatic Neoplasms

Intervention

Procedure:
• Multiparametric magnetic resonance
MRI uses a powerful magnetic field, pulsed radiofrequency and a computer to create detailed images of organs, soft tissues, bones, and practically the rest of the internal structures of the body. MRI does not use ionizing radiation (X-rays).

Locations

Country	Name	City	State
Spain	Francisco Gómez Veiga	Salamanca

Sponsors (2)

Lead Sponsor	Collaborator
InvestigatorUrologyIBSAL	Instituto de Investigación Biomédica de Salamanca

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Comparation between transrectal and transperineal prostatic biopsy with o without Magnetic Resonance	Establish if there are differences between the transrectal and transperineal prostatic biopsy schemes in both cases with and without MRI, in patients with suspected clinical risk of prostate cancer (total PSA between 3 and 20 ng / mL, free PSA index / Total PSA less than 20% and normal or abnormal rectal examination) in terms of efficacy measured by the detection rate and tumor aggressiveness of the tumors detected, complication rates and cost analysis.	6 months